Combination therapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new treatment combining stereotactic radiation (SFRT), the immunotherapy tislelizumab, and platinum chemotherapy for people with stage III non-small cell lung cancer that can't be removed with surgery. It aims to see if this combination helps shrink or control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage III non-small cell lung cancer (the most common type of lung cancer).
- Your cancer cannot be removed with surgery, as decided by your cancer care team.
- Your cancer is at a specific stage (T3-4N1-2M0), meaning it has spread to nearby lymph nodes but not to other parts of the body.
- You have not taken part in any other experimental drug study in the past 3 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation therapy, an immunotherapy drug (tislelizumab), and chemotherapy to shrink bulky stage III lung cancer before possible surgery. The goal is to see if this approach is safe and effective.
This trial tests a combination of radiation, an immunotherapy drug called tislelizumab, and chemotherapy given before surgery for non-small cell lung cancer that has not spread too far (stage II-III). The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
This trial tests a new combination of treatments for advanced non-small cell lung cancer (NSCLC) that has not been treated before. It combines a type of immunotherapy (envafolimab) with a drug that may slow blood vessel growth (endostar) and a special type of radiation therapy (SRT). This may help shrink tumors and control the cancer for a longer time.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.